Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer

P. Pronzato, F. Bruna, E. Neri, D. Roveri, A. Trabucchi, M. Vanoli, A. Vigani, F. Vaira, P. Losardo, G. Bertelli

Research output: Contribution to journalArticle

Abstract

Background. The role of chemotherapy alone or added to radiation treatment for the palliation of multiple, unresectable brain metastases from non small cell lung cancer (NSCLC), is not yet well defined. Carboplatin and teniposide, however, are an interesting combination in this setting since they are active in NSCLC and because of encouraging results against brain metastases in other tumor types. Methods. Twenty patients with brain metastases from NSCLC were treated with whole brain irradiation (total dose of 45 Gy) and chemotherapy (carboplatin, 300 mg/sm on day 1 and teniposide, 60 mg/sm on days 1, 2 and 3). Results. Nine patients (45%) showed a complete remission of neurologic symptoms, and 7 (35%) an improvement. Neurologic signs disappeared in 8 patients (40%) and improved in 7 (35%). Three patients (15%) had partial (50%) regression of brain metastases at CT scan, and also showed response in other tumor sites. One other patient had a response of chest and liver lesions, while the cerebral metastases remained stable. Median survival was 7 months with a range of 1-9 months. Toxicity was mild, with no toxic deaths. Conclusions. Aggressive treatment can be taken into consideration also in the case of NSCLC patients with brain metastases and negative prognostic features. Their participation in clinical trials should be encouraged, since this will allow definition of the contribution of combined radiotherapy, chemotherapy and supportive care to the quality and duration of the patient's life.

Original languageEnglish
Pages (from-to)517-519
Number of pages3
JournalAnticancer Research
Volume15
Issue number2
Publication statusPublished - 1995

Fingerprint

Teniposide
Carboplatin
Non-Small Cell Lung Carcinoma
Radiotherapy
Neoplasm Metastasis
Brain
Neurologic Manifestations
Drug Therapy
Quality of Health Care
Poisons
Neoplasms
Thorax
Clinical Trials
Radiation
Survival
Liver
Therapeutics

Keywords

  • Brain metastases
  • Carboplatin
  • Non-small cell lung cancer
  • Teniposide (VM-26)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pronzato, P., Bruna, F., Neri, E., Roveri, D., Trabucchi, A., Vanoli, M., ... Bertelli, G. (1995). Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer. Anticancer Research, 15(2), 517-519.

Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer. / Pronzato, P.; Bruna, F.; Neri, E.; Roveri, D.; Trabucchi, A.; Vanoli, M.; Vigani, A.; Vaira, F.; Losardo, P.; Bertelli, G.

In: Anticancer Research, Vol. 15, No. 2, 1995, p. 517-519.

Research output: Contribution to journalArticle

Pronzato, P, Bruna, F, Neri, E, Roveri, D, Trabucchi, A, Vanoli, M, Vigani, A, Vaira, F, Losardo, P & Bertelli, G 1995, 'Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer', Anticancer Research, vol. 15, no. 2, pp. 517-519.
Pronzato, P. ; Bruna, F. ; Neri, E. ; Roveri, D. ; Trabucchi, A. ; Vanoli, M. ; Vigani, A. ; Vaira, F. ; Losardo, P. ; Bertelli, G. / Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer. In: Anticancer Research. 1995 ; Vol. 15, No. 2. pp. 517-519.
@article{4f19326853e24bc5a19f5b167e64c0e1,
title = "Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer",
abstract = "Background. The role of chemotherapy alone or added to radiation treatment for the palliation of multiple, unresectable brain metastases from non small cell lung cancer (NSCLC), is not yet well defined. Carboplatin and teniposide, however, are an interesting combination in this setting since they are active in NSCLC and because of encouraging results against brain metastases in other tumor types. Methods. Twenty patients with brain metastases from NSCLC were treated with whole brain irradiation (total dose of 45 Gy) and chemotherapy (carboplatin, 300 mg/sm on day 1 and teniposide, 60 mg/sm on days 1, 2 and 3). Results. Nine patients (45{\%}) showed a complete remission of neurologic symptoms, and 7 (35{\%}) an improvement. Neurologic signs disappeared in 8 patients (40{\%}) and improved in 7 (35{\%}). Three patients (15{\%}) had partial (50{\%}) regression of brain metastases at CT scan, and also showed response in other tumor sites. One other patient had a response of chest and liver lesions, while the cerebral metastases remained stable. Median survival was 7 months with a range of 1-9 months. Toxicity was mild, with no toxic deaths. Conclusions. Aggressive treatment can be taken into consideration also in the case of NSCLC patients with brain metastases and negative prognostic features. Their participation in clinical trials should be encouraged, since this will allow definition of the contribution of combined radiotherapy, chemotherapy and supportive care to the quality and duration of the patient's life.",
keywords = "Brain metastases, Carboplatin, Non-small cell lung cancer, Teniposide (VM-26)",
author = "P. Pronzato and F. Bruna and E. Neri and D. Roveri and A. Trabucchi and M. Vanoli and A. Vigani and F. Vaira and P. Losardo and G. Bertelli",
year = "1995",
language = "English",
volume = "15",
pages = "517--519",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer

AU - Pronzato, P.

AU - Bruna, F.

AU - Neri, E.

AU - Roveri, D.

AU - Trabucchi, A.

AU - Vanoli, M.

AU - Vigani, A.

AU - Vaira, F.

AU - Losardo, P.

AU - Bertelli, G.

PY - 1995

Y1 - 1995

N2 - Background. The role of chemotherapy alone or added to radiation treatment for the palliation of multiple, unresectable brain metastases from non small cell lung cancer (NSCLC), is not yet well defined. Carboplatin and teniposide, however, are an interesting combination in this setting since they are active in NSCLC and because of encouraging results against brain metastases in other tumor types. Methods. Twenty patients with brain metastases from NSCLC were treated with whole brain irradiation (total dose of 45 Gy) and chemotherapy (carboplatin, 300 mg/sm on day 1 and teniposide, 60 mg/sm on days 1, 2 and 3). Results. Nine patients (45%) showed a complete remission of neurologic symptoms, and 7 (35%) an improvement. Neurologic signs disappeared in 8 patients (40%) and improved in 7 (35%). Three patients (15%) had partial (50%) regression of brain metastases at CT scan, and also showed response in other tumor sites. One other patient had a response of chest and liver lesions, while the cerebral metastases remained stable. Median survival was 7 months with a range of 1-9 months. Toxicity was mild, with no toxic deaths. Conclusions. Aggressive treatment can be taken into consideration also in the case of NSCLC patients with brain metastases and negative prognostic features. Their participation in clinical trials should be encouraged, since this will allow definition of the contribution of combined radiotherapy, chemotherapy and supportive care to the quality and duration of the patient's life.

AB - Background. The role of chemotherapy alone or added to radiation treatment for the palliation of multiple, unresectable brain metastases from non small cell lung cancer (NSCLC), is not yet well defined. Carboplatin and teniposide, however, are an interesting combination in this setting since they are active in NSCLC and because of encouraging results against brain metastases in other tumor types. Methods. Twenty patients with brain metastases from NSCLC were treated with whole brain irradiation (total dose of 45 Gy) and chemotherapy (carboplatin, 300 mg/sm on day 1 and teniposide, 60 mg/sm on days 1, 2 and 3). Results. Nine patients (45%) showed a complete remission of neurologic symptoms, and 7 (35%) an improvement. Neurologic signs disappeared in 8 patients (40%) and improved in 7 (35%). Three patients (15%) had partial (50%) regression of brain metastases at CT scan, and also showed response in other tumor sites. One other patient had a response of chest and liver lesions, while the cerebral metastases remained stable. Median survival was 7 months with a range of 1-9 months. Toxicity was mild, with no toxic deaths. Conclusions. Aggressive treatment can be taken into consideration also in the case of NSCLC patients with brain metastases and negative prognostic features. Their participation in clinical trials should be encouraged, since this will allow definition of the contribution of combined radiotherapy, chemotherapy and supportive care to the quality and duration of the patient's life.

KW - Brain metastases

KW - Carboplatin

KW - Non-small cell lung cancer

KW - Teniposide (VM-26)

UR - http://www.scopus.com/inward/record.url?scp=0029055686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029055686&partnerID=8YFLogxK

M3 - Article

C2 - 7539236

AN - SCOPUS:0029055686

VL - 15

SP - 517

EP - 519

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -